ArticleTranslational cancer research2026
TRIM47 promotes cell viability, cell cycle progression, metabolic reprogramming, and inhibits apoptosis of glioma via the NF-κB signaling pathway.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma is recognized as one of the most aggressive primary brain tumors with a poor prognosis. Although TRIM47 is linked to tumorigenesis in cancers, its role and the mechanisms involved in glioma are still not clear. The aim of this study is to elucidate the role and mechanism of TRIM47 in glioma. Methods: TRIM47 expression in glioma tissues and glioma cell lines was assessed via immunohistochemistry, quantitative real-time polymerase chain reaction, and Western blot. Cell Counting Kit-8 and flow cytometry assays evaluated cell viability, cell cycle, apoptosis, and glucose uptake. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured by Extracellular Flux Analyzer. Western blot detected alterations in cleaved caspase-3, pyruvate kinase M2, nuclear factor kappa B (NF-κB) and phosphorylation of NF-κB (p-NF-κB). Genetic knockdown/overexpression and NF-κB signaling pathway inhibitor treatment elucidated the regulatory mechanism of TRIM47 on tumor growth and metabolic reprogramming in male BALB/c nude mice and glioma cell lines. Results: TRIM47 expression was found to be significantly increased in glioma tissues and cell lines. Moreover, elevated TRIM47 expression was linked to reduced overall survival in glioblastoma patients. The suppression of TRIM47 significantly reduced glioma cell viability, resulted in cell cycle arrest in the G1 phase, promoted apoptosis, increased OCR, and decreased ECAR, glucose uptake, and lactate production. Conversely, overexpression of TRIM47 enhanced glioma cell growth and metabolic reprogramming, which could be reversed by treatment with the NF-κB inhibitor PDTC. Conclusions: Collectively, our findings indicate that TRIM47 promotes glioma progression through metabolic reprogramming and activation of the NF-κB signaling pathway, suggesting that TRIM47 is a potential therapeutic target for glioma treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.